Health
Data from GNT-018-IDES Trial Supports Feasibility of imlifidase as Pretreatment in Gene Therapy Treatment for Patients With Crigler–Najjar Syndrome Who Are Immune to AAV
PARIS, October 10, 2025--A significant advance in treatment of patients with immunity to AAVs previously ineligible for clinical trials and existing gene therapy treatments.
About this update from Hansa Biopharma Ab
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/289df04ed3d3d901dbaf369ec2ea186f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3aSF2qU4NV_AwU9KzfJ2Sg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/289df04ed3d3d901dbaf369ec2ea186f","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/YALZPhoxc.up0vhjNkRiOg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/289df04ed3d3d901dbaf369ec2ea186f","width":1024,"height":512}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":640,"height":229,"url":"https://media.zenfs.com/en/business-wire.com/6c730901bfc48735aae76c44974cdada"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TZR_z5Gv7r14TtsftZljuA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM0NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/6c730901bfc48735aae76c44974cdada","width":640,"height":229}}},{"type":"text","content":"Results presented today at ESGCT 2025","length":37,"tagName":"p","attribs":{}},{"type":"text","content":"PARIS, October 10, 2025--(BUSINESS WIRE)--Genethon, a worldwide pioneer and leader in research and development of gene therapy for rare genetic diseases, and Hansa Biopharma, a Sweden-based leader in IgG cleaving enzyme technology announced today that a patient with a rare liver disease and immunity to the AAV vector has been successfully treated with Genethon’s AAV-based GNT0003 gene therapy for Crigler-Najjar syndrome, following prior administration of imlifidase, an enzyme capable of temporarily inhibiting the immune response. This encouraging result, achieved in a clinical trial, is a significant advance in the treatment of patients with immunity to AAVs who were previously ineligible for clinical trials and existing gene therapy treatments.","length":755,"tagName":"p"},{"type":"text","content":"Gene therapy involves injecting a gene drug into an organism using a vector, a "means of transport" usually derived from viruses, such as AAVs (adeno-associated viruses), which are commonly used for gene the...